| |
|
May 14, 2013: SGLT2 Special Edition Issue 2
(Recommend Us)
|
 |
|
Exclusive Interviews |
|
|
|
|
How It Works |
|
|
|
|
|
|
Top Articles |
|
|
|
|
|
|
|
|
Exclusive Interviews |
|
Prescribers Discuss the Use of SGLT2 Inhibitors
Often, when a new class of drugs receives FDA approval, we hear from the investigators or medical professionals involved in the original studies and clinical trials and, although they may possess the most knowledge, they are often the least likely to fairly represent the opinions of most medical professionals. For this special issue we have reached out to medical professionals across the country for their thoughts and opinions to find out what they really think about SGLT-2 Inhibitors....
|
|
|
|
How It Works |
|
Sodium Glucose Cotransporter 2-Inhibitor Prescription Coverage
David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control
Recently, I was chatting electronically with Irl B. Hirsch, MD, Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine. I asked him if he had been using Invokana with his patients, and he sent me back this message: "No, not yet, and not likely to anytime soon due to lack of (prescription) coverage in this part of the country. Will be interesting to see if the experience of others matches the clinical trials."
Click here for Sodium Glucose Cotransporter 2-Inhibitor Prescription Coverage
|
|
|
AACE Presentations of SGLT-2 Inhibitor Data
David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control
Lauren Self, University of Florida College of Pharmacy, PharmD Candidate
When the finest, most talented endocrinologists get together for a conference, you can bet that there will be a lot of great information on the latest in diabetes care. This year it seems that research on the SGLT2-Inhibitor class was the most important and garnered the most attention. We have pulled together all of the presentations and abstracts from this year's AACE meeting for you to review.
Click here for AACE Presentations of SGLT-2 Inhibitor Data
|
|
|
|
Top Articles |
|
|
|
|
|
|
|
Merck and Pfizer Collaborate to Develop New SGLT2 Drug, Ertugliflozin
There is currently fierce competition to get SGLT2 medications approved and onto the market. The first SGLT2 drug, Invokana (canagliflozin), developed by Johnson and Johnson, was approved by the FDA just a few weeks ago. Ertugliflozin, which is ready for Phase III trials, will likely be marketed as a drug taken on its own as a fixed-dose, or in combination with metformin and Januvia (sitagliptin), both oral antihyperglycemic agents.
Click here for Merck and Pfizer Collaborate to Develop New SGLT2 Drug, Ertugliflozin
|
|
Diabetes In Control Has Over 12500 Studies & Articles In Our Archives
|
|
Most Popular Articles of the Month
|
Quote of the Week!
|
"The poor man is not he who is without a cent, but he who is without a dream."
...............Harry Kemp
Diabetes in Control wishes to gratefully acknowledge the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:
Lauren Self, 2014 PharmD Candidate, University of Florida
Cale Courtney, 2014 PharmD Candidate, University of Florida
|
|
|
|
|
|
Cast Your Vote
Should a person newly diagnosed with prediabetes be treated with medication along with lifestyle changes?
Navigate Diabetes In Control
|
|
Search Articles On Diabetes In Control
|
|
|
